[ENDP] Endo International plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 16.27 Change: 0.5 (3.17%)
Ext. hours: 16.25 Change: -0.02 (-0.12%)

chart ENDP

Refresh chart

Strongest Trends Summary For ENDP

ENDP is in the medium-term up 13% in 2 months and down -33% below S&P in 6 months. In the long-term down -89% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women?s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men?s and women?s health, and prostate health. The company?s products also inc

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-1.55% Sales Growth - 4 Quarters -15.23% Sales Growth - Q/Q-10.73% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.55% ROE-8.7% ROI-3.62%
Current Ratio1.55 Quick Ratio1.37 Long Term Debt/Equity2.86 Debt Ratio0.83
Gross Margin49.62% Operating Margin-27.98% Net Profit Margin-11.54% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities996.86 M Cash From Operating Activities-930.48 M Gross Profit329.86 M
Net Profit-89.81 M Operating Profit45.75 M Total Assets14.15 B Total Current Assets5.33 B
Total Current Liabilities3.44 B Total Debt5.39 B Total Liabilities10.01 B Total Revenue714.13 M
Technical Data
High 52 week18.3 Low 52 week5.43 Last close10.32 Last change0.19%
RSI62.45 Average true range0.41 Beta0.73 Volume2.59 M
Simple moving average 20 days7.05% Simple moving average 50 days4.64% Simple moving average 200 days-11.66%
Performance Data
Performance Week9.9% Performance Month24.04% Performance Quart-39.58% Performance Half-15.41%
Performance Year57.8% Performance Year-to-date41.37% Volatility daily2.91% Volatility weekly6.5%
Volatility monthly13.31% Volatility yearly46.12% Relative Volume179.67% Average Volume3.76 M
New High New Low

News

2019-03-25 16:24:10 | Endo International: Wall Street Ratings Not Very Favorable?

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-19 07:30:00 | Endo Announces Publication Of Collagenase Clostridium Histolyticum CCH Phase 2 Data In Dermatologic Surgery

2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up

2019-03-14 20:06:00 | Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations

2019-03-14 20:06:00 | Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

2019-03-14 12:01:16 | Endo Finance Co. -- Moody's downgrades Endo's secured debt to Ba3, unsecured notes to Caa1; B2 CFR affirmed

2019-03-14 11:01:03 | Insys Plunges on Auditor's Concern About Insufficient Funds

2019-03-14 07:54:00 | Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes

2019-03-14 07:51:00 | Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

2019-03-12 09:35:01 | Is Endo International ENDP a Great Stock for Value Investors?

2019-03-11 13:13:34 | Opioid litigation concerns weigh on pharmaceutical loan borrowers

2019-03-11 10:30:56 | What’s Expected to Drive Endo’s Growth in Fiscal 2019?

2019-03-11 09:00:57 | Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts

2019-03-11 07:31:56 | How Endo’s and Mallinckrodt’s Expense Control Stacks Up

2019-03-08 14:40:02 | Endo International’s and Mallinckrodt’s EPS Growth Expectations

2019-03-08 13:10:02 | Comparing Endo’s and Mallinckrodt’s Revenue Forecasts

2019-03-08 11:37:59 | Analysts’ Views on Endo International and Mallinckrodt

2019-03-08 08:56:01 | Endo ENDP Soars: Stock Adds 6% in Session

2019-03-08 06:00:00 | State Pensions Fought Guns and Tobacco. Why Aren’t They Divesting From Opioids?

2019-03-07 07:35:00 | Report: Exploring Fundamental Drivers Behind Procter & Gamble, Consolidated Edison, Lennar, Endo International plc, Box, and FRONT YARD RESIDENTIAL CORP — New Horizons, Emerging Trends, and Upcoming Developments

2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-03-05 11:12:06 | FDA ruling on compounding goes Endo's way

2019-03-04 12:45:42 | Endo International plc NASDAQ:ENDP Insiders Have Been Selling

2019-03-04 08:39:01 | Implied Volatility Surging for Endo ENDP Stock Options

2019-03-04 08:00:00 | Endo to Participate at Cowen & Company 39th Annual Healthcare Conference

2019-03-01 18:04:57 | Endo gains on favorable FDA drug compounding decision

2019-03-01 15:27:00 | Endo Announces FDA Decision Not to Include Vasopressin on 503B Bulks List

2019-03-01 14:20:07 | Endo ENDP Q4 Earnings & Revenues Beat Estimates, Shares Up

2019-03-01 07:30:00 | Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting

2019-02-28 16:21:26 | Edited Transcript of ENDP earnings conference call or presentation 28-Feb-19 12:30pm GMT

2019-02-28 11:42:17 | Endo International plc ENDP Q4 2018 Earnings Conference Call Transcript

2019-02-28 06:30:00 | Endo Reports Fourth-Quarter And Full Year 2018 Financial Results

2019-02-27 17:15:00 | Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited

2019-02-22 07:30:00 | Paladin Labs Inc. Announces Approval of Envarsus PA™ tacrolimus prolonged-release tablets in Canada

2019-02-21 10:31:03 | Earnings Preview: Endo International ENDP Q4 Earnings Expected to Decline

2019-02-08 08:06:41 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-02-07 12:59:17 | FDA files motion to delay Endo litigation, again

2019-02-07 08:00:00 | Endo Agrees Not To Oppose Additional Stay of FDA Litigation Following Restoration of Government Appropriations

2019-01-28 08:00:00 | Today's Research Reports on Trending Tickers: OPKO Health and Endo International

2019-01-25 17:22:00 | Endo to Announce Fourth-Quarter and Full-Year 2018 Financial Results

2019-01-19 08:06:27 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-01-17 08:07:03 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-01-15 08:06:34 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-01-09 08:07:17 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-01-08 11:34:11 | Albany region cities sue pharmaceutical companies over opioid epidemic

2019-01-02 11:25:00 | Government shutdown puts Endo-FDA lawsuit in limbo

2019-01-02 06:58:11 | Heron Gains on Priority Review Designation for Pain Drug

2018-12-31 08:52:01 | Options Traders Expect Huge Moves in Endo ENDP Stock

2018-12-31 07:30:00 | Endo Announces Anticipated Further Stay of Compounding Litigation Due to Lapse of Government Appropriations